Rubraca

Morgan Stanley said in a note Tuesday it would be buyers of Clovis Oncology Inc (NASDAQ: CLVS) and TESARO Inc (NASDAQ: TSRO) ahead of the Lynparza label decision. AstraZeneca plc (ADR) (NYSE: AZN)'s Lynparza is a poly polymerase, or PARP, inhibitor indicated for use as a monotherapy in patients...

Analysts at Leerink maintain an Outperform rating on shares ofClovis Oncology Inc (NASDAQ: CLVS) with a price target boosted from $85 to $114 after the company hosted a conference call on Monday, which addressed some of the biggest controversies it faces. Clovis' conference calls came after the...

TESARO Inc (NASDAQ: TSRO) announced the FDA approval of Zejula (niraparib) in recurrent ovarian cancer maintenance with a broad label. The approval came in three months ahead of schedule and the launch is expected in late April, Baird’s Michael E. Ulz said in a report. While reiterating a...

The incidence of ovarian cancer is supposed to be sporadic, with just about 3 percent of cancers among women said to originate from the ovaries. However, it is considered more lethal than any other cancer of female reproductive system. Clovis' Slice Of Luck So when the FDA granted accelerated...

Shares of Clovis Oncology Inc (NASDAQ: CLVS) initially spiked more than 12 percent on Monday following surprise news from the FDA that is has approved advanced ovarian cancer drug Rubraca. The FDA ruling caught the market off-guard because a ruling wasn't expected until February, and Clovis...

Shares of Clovis Oncology Inc (NASDAQ: CLVS) soared higher by more than 15 percent Monday after the U.S. Food and Drug Administration granted an accelerated approval for the company's PARP inhibitor rucaparib for the treatment of women with advanced ovarian cancer which will now be branded...